• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home StudyGraphics

#VisualAbstract: Intravenous thrombolysis plus endovascular treatment may be more efficacious for acute ischemic stroke

byMinjee Kim
October 13, 2023
in StudyGraphics
Reading Time: 2 mins read
#VisualAbstract: Intravenous thrombolysis plus endovascular treatment may be more efficacious for acute ischemic stroke
Share on FacebookShare on TwitterShare on LinkedIn

1. The 90-day modified Ranking Scale score was comparable for patients in intravenous thrombolysis plus endovascular treatment versus endovascular treatment alone.

2. Intracranial hemorrhage was less frequent in the endovascular treatment alone group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Intravenous thrombolysis before endovascular treatment is the preferred therapy among patients with acute ischemic stroke; however, its utility among patients directly admitted to endovascular treatment centers remains unknown. This systematic review and meta-analysis aimed to assess the non-inferiority of endovascular treatment alone versus intravenous thrombolysis plus endovascular treatment. The primary outcome was a 90-day modified Rankin Scale (mRS) score, while the key secondary outcome was the presence of intracranial hemorrhage. According to study results, non-inferiority could not be established between endovascular treatment alone and intravenous thrombolysis plus endovascular treatment. Any-grade intracranial hemorrhage was less common with the endovascular treatment alone group, but symptomatic intracranial hemorrhage did not differ between groups. Thus, although this study was well done, it was limited by the absence of a definitive conclusion about the efficacy of both treatments among patients admitted directly to endovascular treatment centers.

Click to read the study in The Lancet

RELATED REPORTS

Asundexian reduced ischemic stroke risk by 26% after recent non-cardioembolic stroke or high-risk transient ischemic attack

In selected patients with anterior-circulation large-vessel stroke 24-72 hours after onset, thrombectomy improved 90-day function but increased hemorrhage and death

Relevant Reading: Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke

FDA approvedFor ischemic stroke: Sunharbo (asundexian), Nov 9, 2026→

In-depth [systematic review and meta-analysis]: A total of 6 randomized-controlled trials (n=2313, 1153 in endovascular treatment alone and 1160 in intravenous thrombolysis and endovascular treatment) were included from database inception to Mar 9, 2023. The primary outcome of median 90-day mRS score was comparable for endovascular treatment and intravenous thrombolysis plus endovascular treatment (3 vs. 2, adjusted odds ratio [aOR] 0.89, 95% confidence interval [CI] 0.76-1.04). Intracranial hemorrhage was less frequent in the endovascular treatment alone group (aOR 0.82, 95% CI 0.68-0.99). However, there were no significant differences in symptomatic intracranial hemorrhage and mortality rates. Findings from this study suggest that the non-inferiority of endovascular treatment alone versus a combined approach in patients directly admitted to endovascular treatment centers was not established.

 

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: acute ischemic strokealteplaseendovascular treatmentintravenous thrombolysisischemic strokestroke
Previous Post

Spiritual care is associated with improved quality of life in patients who underwent intracranial hemorrhage surgery

Next Post

Long-term heat exposure associated with severe maternal morbidity

RelatedReports

TIA collage: a calm older man, a neck artery traced by a teal ribbon, an hourglass and folded reading glasses
2MM Trial Briefs

Asundexian reduced ischemic stroke risk by 26% after recent non-cardioembolic stroke or high-risk transient ischemic attack

November 10, 2026
Stroke treatment collage: an engraved brain with teal arteries and one blocked branch, a coiled catheter and a stopwatch
Emergency

In selected patients with anterior-circulation large-vessel stroke 24-72 hours after onset, thrombectomy improved 90-day function but increased hemorrhage and death

November 7, 2026
Cannabis and mental health collage: a thoughtful young man with curly hair, a flat cannabis leaf and three blank shopfronts
Cardiology

Cannabis use, including smoked or edible, linked to higher stroke risk

November 6, 2026
A detailed illustration of a kidney and glomeruli, with a pill depicted, representing treatment for kidney-related conditions. It suggests a focus on chronic kidney disease.
Nephrology

Apixaban (Eliquis) is associated with reduced rates of ischemic stroke and bleeding in patients with atrial fibrillation and advanced chronic kidney disease compared with warfarin (Coumadin)

September 9, 2026
Next Post

Long-term heat exposure associated with severe maternal morbidity

Blood type correlates with egg reserve in infertile women

Edoxaban does not improve outcomes in patients with atrial high-rate episodes

#VisualAbstract: Optical Coherence Tomography–Guided versus Angiography-Guided Percutaneous Coronary Intervention (PCI)

#VisualAbstract: Optical Coherence Tomography–Guided versus Angiography-Guided Percutaneous Coronary Intervention (PCI)

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Pelacarsen lowers lipoprotein(a) but does not reduce major cardiovascular events in patients with established cardiovascular disease
  • Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer
  • CDC reports 5,412 confirmed measles cases in the United States in 2026
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.